Medicare AdvantageAdministrativeLow impact
MA11.022a, Cryosurgical Ablation of the Prostate Gland
Independence Blue Cross·NJ · Urology, Oncology, Radiation Oncology·Medical Policy
Effective date
Jan 21, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued MA11.022a (Cryosurgical Ablation of the Prostate Gland) effective 01/21/2026 with no substantive coverage changes. The policy continues to cover cryosurgical ablation as primary treatment for localized prostate cancer (T1-T3) and as salvage therapy for recurrent disease meeting specific criteria, while maintaining experimental/investigational status for subtotal cryoablation. This is a routine annual review reissuance with no billing or coverage modifications.
Action Required
No immediate action required. Billing team should note the new effective date (01/21/2026) and ensure current documentation practices remain compliant: medical records must demonstrate medical necessity for prostate cancer staging (T1-T3 for primary treatment, T2B or below with Gleason <9 and PSA <8 for salvage therapy). Continue to deny claims for subtotal cryoablation (CPT 55873) as experimental/investigational. Maintain current prior authorization and documentation verification processes; no workflow changes are needed.